NYSE:ZTSPharmaceuticals
Zoetis (ZTS) Valuation in Focus Following Q3 Growth and New Cat Therapy Approval
Zoetis, Inc. reported its third quarter earnings along with a revenue guidance update for 2025, giving investors a transparent view of operational stability. The company’s recent product approval in Europe further underscores its focus on innovation.
See our latest analysis for Zoetis.
While Zoetis delivered year-over-year growth in both revenue and net income, plus expanded its European product lineup, recent share price momentum tells a different story. The stock closed at $120.24 after a...